Dongwha Pharm.Co.,Ltd

KOSE:A000020 Stock Report

Market Cap: ₩239.5b

Dongwha Pharm.Co.Ltd Balance Sheet Health

Financial Health criteria checks 5/6

Dongwha Pharm.Co.Ltd has a total shareholder equity of ₩408.2B and total debt of ₩30.8B, which brings its debt-to-equity ratio to 7.5%. Its total assets and total liabilities are ₩565.0B and ₩156.8B respectively. Dongwha Pharm.Co.Ltd's EBIT is ₩18.7B making its interest coverage ratio -2.9. It has cash and short-term investments of ₩88.8B.

Key information

7.5%

Debt to equity ratio

₩30.80b

Debt

Interest coverage ratio-2.9x
Cash₩88.83b
Equity₩408.21b
Total liabilities₩156.76b
Total assets₩564.97b

Recent financial health updates

Recent updates

Dongwha Pharm.Co.Ltd's (KRX:000020) Promising Earnings May Rest On Soft Foundations

Mar 26
Dongwha Pharm.Co.Ltd's (KRX:000020) Promising Earnings May Rest On Soft Foundations

Is Dongwha Pharm.Co.,Ltd (KRX:000020) A Smart Pick For Income Investors?

Apr 28
Is Dongwha Pharm.Co.,Ltd (KRX:000020) A Smart Pick For Income Investors?

These 4 Measures Indicate That Dongwha Pharm.Co.Ltd (KRX:000020) Is Using Debt Safely

Mar 11
These 4 Measures Indicate That Dongwha Pharm.Co.Ltd (KRX:000020) Is Using Debt Safely

Dongwha Pharm.Co.,Ltd (KRX:000020) Has A ROE Of 8.6%

Feb 22
Dongwha Pharm.Co.,Ltd (KRX:000020) Has A ROE Of 8.6%

Is Dongwha Pharm.Co.Ltd's (KRX:000020) Share Price Gain Of 102% Well Earned?

Feb 07
Is Dongwha Pharm.Co.Ltd's (KRX:000020) Share Price Gain Of 102% Well Earned?

Should Dongwha Pharm.Co.,Ltd (KRX:000020) Be Part Of Your Dividend Portfolio?

Jan 23
Should Dongwha Pharm.Co.,Ltd (KRX:000020) Be Part Of Your Dividend Portfolio?

Is Dongwha Pharm.Co.,Ltd (KRX:000020) Popular Amongst Insiders?

Jan 08
Is Dongwha Pharm.Co.,Ltd (KRX:000020) Popular Amongst Insiders?

Dongwha Pharm.Co.,Ltd (KRX:000020) Pays A ₩120 Dividend In Just Four Days

Dec 24
Dongwha Pharm.Co.,Ltd (KRX:000020) Pays A ₩120 Dividend In Just Four Days

We're Not Counting On Dongwha Pharm.Co.Ltd (KRX:000020) To Sustain Its Statutory Profitability

Dec 19
We're Not Counting On Dongwha Pharm.Co.Ltd (KRX:000020) To Sustain Its Statutory Profitability

Is Dongwha Pharm.Co.Ltd (KRX:000020) Using Too Much Debt?

Dec 04
Is Dongwha Pharm.Co.Ltd (KRX:000020) Using Too Much Debt?

Can Dongwha Pharm.Co.,Ltd (KRX:000020) Improve Its Returns?

Nov 19
Can Dongwha Pharm.Co.,Ltd (KRX:000020) Improve Its Returns?

Financial Position Analysis

Short Term Liabilities: A000020's short term assets (₩237.7B) exceed its short term liabilities (₩105.0B).

Long Term Liabilities: A000020's short term assets (₩237.7B) exceed its long term liabilities (₩51.8B).


Debt to Equity History and Analysis

Debt Level: A000020 has more cash than its total debt.

Reducing Debt: A000020's debt to equity ratio has increased from 0% to 7.5% over the past 5 years.

Debt Coverage: A000020's debt is well covered by operating cash flow (94.7%).

Interest Coverage: A000020 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.